Enorama Pharma Ab Stock Net Income
| ERMA Stock | SEK 1.05 0.40 27.59% |
As of the 16th of February 2026, Enorama Pharma shows the Mean Deviation of 7.2, standard deviation of 13.97, and Variance of 195.12. Enorama Pharma AB technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Analyzing historical trends in various income statement and balance sheet accounts from Enorama Pharma's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Enorama Pharma's valuation are summarized below:Enorama Pharma AB does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Enorama |
Enorama Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Enorama Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Enorama Pharma.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Enorama Pharma on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Enorama Pharma AB or generate 0.0% return on investment in Enorama Pharma over 90 days. Enorama Pharma is related to or competes with Klaria Pharma, Isofol Medical, Annexin Pharmaceuticals, Clinical Laserthermia, SenzaGen, IZafe Group, and Integrum. Enorama Pharma AB , a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven ... More
Enorama Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Enorama Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Enorama Pharma AB upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 77.61 | |||
| Value At Risk | (17.61) | |||
| Potential Upside | 13.86 |
Enorama Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Enorama Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Enorama Pharma's standard deviation. In reality, there are many statistical measures that can use Enorama Pharma historical prices to predict the future Enorama Pharma's volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.90) | |||
| Total Risk Alpha | (1.64) | |||
| Treynor Ratio | (0.12) |
Enorama Pharma February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.11) | |||
| Mean Deviation | 7.2 | |||
| Coefficient Of Variation | (2,346) | |||
| Standard Deviation | 13.97 | |||
| Variance | 195.12 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.90) | |||
| Total Risk Alpha | (1.64) | |||
| Treynor Ratio | (0.12) | |||
| Maximum Drawdown | 77.61 | |||
| Value At Risk | (17.61) | |||
| Potential Upside | 13.86 | |||
| Skewness | 1.95 | |||
| Kurtosis | 9.3 |
Enorama Pharma AB Backtested Returns
Enorama Pharma AB secures Sharpe Ratio (or Efficiency) of -0.0389, which denotes the company had a -0.0389 % return per unit of risk over the last 3 months. Enorama Pharma AB exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Enorama Pharma's Mean Deviation of 7.2, variance of 195.12, and Standard Deviation of 13.97 to check the risk estimate we provide. The firm shows a Beta (market volatility) of 4.86, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Enorama Pharma will likely underperform. At this point, Enorama Pharma AB has a negative expected return of -0.57%. Please make sure to confirm Enorama Pharma's total risk alpha, maximum drawdown, potential upside, as well as the relationship between the treynor ratio and value at risk , to decide if Enorama Pharma AB performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.56 |
Modest predictability
Enorama Pharma AB has modest predictability. Overlapping area represents the amount of predictability between Enorama Pharma time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Enorama Pharma AB price movement. The serial correlation of 0.56 indicates that roughly 56.0% of current Enorama Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.56 | |
| Spearman Rank Test | 0.72 | |
| Residual Average | 0.0 | |
| Price Variance | 0.12 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Enorama Pharma AB reported net income of (27.74 Million). This is 108.13% lower than that of the Healthcare sector and 92.8% lower than that of the Drug Manufacturers - Specialty & Generic industry. The net income for all Sweden stocks is 104.86% higher than that of the company.
Enorama Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enorama Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Enorama Pharma could also be used in its relative valuation, which is a method of valuing Enorama Pharma by comparing valuation metrics of similar companies.Enorama Pharma is currently under evaluation in net income category among its peers.
Enorama Fundamentals
| Return On Equity | -32.88 | |||
| Return On Asset | -0.53 | |||
| Operating Margin | (3.11) % | |||
| Current Valuation | 42.1 M | |||
| Shares Outstanding | 10.69 M | |||
| Shares Owned By Insiders | 78.21 % | |||
| Shares Owned By Institutions | 1.31 % | |||
| Price To Book | 7.67 X | |||
| Price To Sales | 3.82 X | |||
| Revenue | 11.04 M | |||
| Gross Profit | 3.9 M | |||
| EBITDA | (25.56 M) | |||
| Net Income | (27.74 M) | |||
| Cash And Equivalents | 2.01 M | |||
| Cash Per Share | 0.38 X | |||
| Total Debt | 1.7 M | |||
| Debt To Equity | 6.00 % | |||
| Current Ratio | 0.52 X | |||
| Book Value Per Share | (1.22) X | |||
| Cash Flow From Operations | (30.16 M) | |||
| Earnings Per Share | (4.92) X | |||
| Number Of Employees | 10 | |||
| Beta | 1.65 | |||
| Market Capitalization | 89.44 M | |||
| Total Asset | 50.93 M | |||
| Z Score | 31.2 | |||
| Net Asset | 50.93 M |
About Enorama Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enorama Pharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enorama Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enorama Pharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Enorama Stock Analysis
When running Enorama Pharma's price analysis, check to measure Enorama Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enorama Pharma is operating at the current time. Most of Enorama Pharma's value examination focuses on studying past and present price action to predict the probability of Enorama Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enorama Pharma's price. Additionally, you may evaluate how the addition of Enorama Pharma to your portfolios can decrease your overall portfolio volatility.